Tasly Pharmaceutical Group (600535.SH) announced that recently its wholly-owned subsidiary Jiangsu Tasly Emperor Yi Pharmaceutical Co., Ltd. ("Jiangsu Emperor Yi") has received the supplementary drug application approval notice for Furmatting Ketotifen Tablets issued by the National Medical Products Administration. The drug is approved through the consistency evaluation of generic drug quality and efficacy. As of now, Jiangsu Emperor Yi's cumulative R&D investment in the consistency evaluation of this drug is RMB 5.4924 million. Furmatting Ketotifen Tablets are used for allergic rhinitis and allergic asthma, and are a Class B drug in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2023)." According to data from Minenet, the sales of Furmatting Ketotifen Tablets in public hospitals in urban and county areas and urban entity pharmacies in China amounted to RMB 66.92 million in 2023.
Tasly Pharmaceutical Group (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tasly Deyi Pharmaceutical Co., Ltd. (referred to as "Jiangsu Deyi"), has received the "Drug Registration Certificate" for the oral solution of Propiverine Hydrochloride. The oral solution of Propiverine Hydrochloride is used to relieve symptoms such as respiratory difficulties caused by obstructive respiratory disorders including bronchial asthma, chronic bronchitis, acute bronchitis, and asthmatic bronchitis. It is classified as a class B variety in the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug List (2023)".
The oral solution of Propiverine Hydrochloride has obtained the Drug Registration Certificate, which is considered equivalent to passing the consistency evaluation and further enriches the company's product pipeline, enhancing its market competitiveness.